http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2011007458-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbd6bfa8cc22494b7aeb6955c3a467b3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2011-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09503d61f12629fcb781ba814a3f42e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_441e14b073893613f5993846c2758b07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_087bd4baa76fbe2ac2b950a2d1b143b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af2a1d698c4201f3ac6d7517f076878a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_565f093d07a637335533a233b2c337f3 |
| publicationDate | 2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2011007458-A |
| titleOfInvention | NEW STABLE POLYETHYLGLYCOL CONJUGATE WITH INTERFERON ALFA, REPRESENTED BY A POSITIONAL ISOMERO. |
| abstract | The invention relates to the pharmaceutical industry and medicine, in particular, to the new interferon-PEG derivatives and to the discovery of a new functionally active and very stable conjugate of interferon with polyethylene glycol with an interferon alpha activity, with reduced immunogenicity, with prolonged biological effects and improved pharmacokinetic parameters of the general formula: (see formula) where: n - integer values from 227 to 10,000, so that the molecular weight of the PEG is approximately 10,000 to 40,000 Da; m - integer = 4; IFN - natural or recombinant polypeptide that shows IFN-alpha activity. Furthermore, the invention relates to medicaments containing declared conjugates of the formula (I), pharmaceutical compositions containing PEG-IFN conjugates and therapeutically acceptable excipients suitable for the treatment of viral infections and cancer, as well as diseases associated with primary or secondary immunodeficiency. The invention is related to the use of a conjugate of formula (I) in medicaments having antiviral, antiproliferative and immunomodulatory activity, with methods for the prevention and / or treatment of diseases associated with primary or secondary immunodeficiency that include the administration of an amount therapeutically effective of the conjugate of the formula (I), and with the package containing said pharmaceutical composition. |
| priorityDate | 2010-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.